[ FDA ENFORCEMENT INTELLIGENCE ]
Learn from the record. Every FDA recall is a quality signal.
Live drug, device & food recall data from the FDA (openFDA enforcement) — food spanning dietary supplements, cosmetics & animal food — mapped to the GxP quality domains SPEQ assesses, so you can see where control breaks down across every regulated industry.
1,000
Total recalls
217
Class I (most serious)
167
Drug
515
Device
318
Food / supplement / cosmetic
Last 12 months · latest report 2026-07-22 · source: openFDA enforcement
RECALLS BY CLASSIFICATION · MONTHLY
RECALL REASONS BY QUALITY DOMAIN
Domain mapping is a SPEQ interpretation of the FDA recall reason, not an official FDA classification.
315 matching recalls
| Date | Class | Firm | Reason | Quality domain |
|---|---|---|---|---|
| 2025-10-22 | Class II | Ascend Laboratories, LLCD-0020-2026 | Failed Dissolution Specifications | Validation & Qualification |
| 2025-10-15 | Class II | Dr. Reddy's Laboratories, Inc.D-0008-2026 | Out-of-Specification (OOS) result during the 6-month stability testing; decreased preservative concentration. | Validation & Qualification |
| 2025-10-15 | Class II | AvKARED-0007-2026 | Failed Content Uniformity Specifications | Validation & Qualification |
| 2025-10-15 | Class II | Acella Pharmaceuticals, LLCD-0014-2026 | Failed dissolution specifications: Stability testing found that the lot did not meet dissolution specifications. | Validation & Qualification |
| 2025-10-15 | Class II | ACCORD HEALTHCARE, INC.D-0006-2026 | Subpotent: During long term stability testing of Levothyroxine Sodium Tablets USP for 88 mcg, the assay content was observed below the approved specification range. | Validation & Qualification |
| 2025-10-08 | Class II | Amerisource Health Services LLCD-0675-2025 | Failed Dissolution Specifications. | Validation & Qualification |
| 2025-10-08 | Class II | Zydus Pharmaceuticals (USA) IncD-0002-2026 | Failed impurity/degradation specifications:Out of Specification result for an individual organic impurity | Validation & Qualification |
| 2025-10-08 | Class III | Stanley Pearlman Enterprises, Inc.H-0641-2025 | Recall initiated due to the wrong best by date (1-11-2025) being printed on the retail bag which would imply that these are expired but in truth they are good until 1-11-2027. | Validation & Qualification |
| 2025-10-08 | Class II | Zydus Pharmaceuticals (USA) IncD-0001-2026 | Failed impurity/degradation specifications:Out of Specification result for an individual organic impurity | Validation & Qualification |
| 2025-10-01 | Class III | Granules Pharmaceuticals Inc.D-0669-2025 | Failed Impurities/Degradation Specifications: | Validation & Qualification |
| 2025-10-01 | Class III | Granules Pharmaceuticals Inc.D-0673-2025 | Failed Impurities/Degradation Specifications: | Validation & Qualification |
| 2025-10-01 | Class III | Medline Industries, LPD-0674-2025 | Subpotent drug | Validation & Qualification |
| 2025-10-01 | Class III | Granules Pharmaceuticals Inc.D-0670-2025 | Failed Impurities/Degradation Specifications: | Validation & Qualification |
| 2025-10-01 | Class III | Granules Pharmaceuticals Inc.D-0671-2025 | Failed Impurities/Degradation Specifications: | Validation & Qualification |
| 2025-10-01 | Class III | Granules Pharmaceuticals Inc.D-0672-2025 | Failed Impurities/Degradation Specifications: | Validation & Qualification |
| 2025-09-24 | Class II | SUN PHARMACEUTICAL INDUSTRIES INCD-0658-2025 | Failed Dissolution Specifications-Out of Specification (OOS) observation for sulphate in Sodium Tartrate Dihydrate used for the production of Mertiatide. | Validation & Qualification |
| 2025-09-24 | Class II | Ascend Laboratories, LLCD-0645-2025 | Superpotent drug | Validation & Qualification |
| 2025-09-24 | Class II | Zydus Pharmaceuticals (USA) IncD-0657-2025 | Failed Impurity/Degradation Specifications | Validation & Qualification |
| 2025-09-24 | Class II | Zydus Pharmaceuticals (USA) IncD-0656-2025 | Failed Impurity/Degradation Specifications | Validation & Qualification |
| 2025-09-17 | Class II | GRACE & FIRE PTY LTDD-0641-2025 | Subpotent/Super-potent Product: Testing of the SPF 50 sunscreen revealed inconsistency in SPF results ranging from SPF 4, 10, 21, 26, 33, 60, 61, and 64. | Validation & Qualification |
| 2025-09-17 | Class II | Exela Pharma Sciences LLCD-0620-2025 | Failed Impurities/Degradation Specifications: out of specification results for arsenic in the impurities tested. | Validation & Qualification |
| 2025-09-17 | Class II | Zydus Pharmaceuticals (USA) IncD-0623-2025 | Failed Impurities/Degradation Specifications: Out-of-Specification test results obtained for any individual unknown degradation impurity. | Validation & Qualification |
| 2025-09-17 | Class III | Dynamic Sports NutritionH-0573-2025 | Dietary supplement involved degradation of an ingredient. Product is sub-potent for Vitamin B12 not meeting label claims. | Validation & Qualification |
| 2025-09-17 | Class II | GRACE & FIRE PTY LTDD-0640-2025 | Subpotent/Super-potent Product: Testing of the SPF 50 sunscreen revealed inconsistency in SPF results ranging from SPF 4, 10, 21, 26, 33, 60, 61, and 64. | Validation & Qualification |
| 2025-09-17 | Class II | Breckenridge Pharmaceutical, Inc.D-0621-2025 | CGMP deviations: N-nitroso-duloxetine impurity above the proposed interim limit. | Validation & Qualification |
Data: U.S. FDA openFDA enforcement API. Quality-domain mapping and severity are a SPEQ editorial interpretation of the recall reason, not an official FDA classification. Recall details are as reported by the FDA.